Elevation Oncology Company Insiders
| ELEV Stock | USD 0.67 0.05 8.06% |
Elevation Oncology employs about 29 people. The company is managed by 10 executives with a total tenure of roughly 68 years, averaging almost 6.0 years of service per executive, having 2.9 employees per reported executive. Recap of Elevation Oncology's management performance can provide insight into the venture performance.
Elevation |
Elevation Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.2546) % which means that it has lost $0.2546 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6367) %, meaning that it created substantial loss on money invested by shareholders. Elevation Oncology's management efficiency ratios could be used to measure how well Elevation Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2025. Return On Capital Employed is likely to drop to -0.51 in 2025. At this time, Elevation Oncology's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to 69.03 in 2025, whereas Net Tangible Assets are likely to drop slightly above 44.2 M in 2025.Common Stock Shares Outstanding is likely to drop to about 28.2 M in 2025. Net Loss is likely to climb to about (81.3 M) in 2025
Elevation Oncology Workforce Comparison
Elevation Oncology is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 94.0. Elevation Oncology totals roughly 29.0 in number of employees claiming about 31% of equities under Health Care industry.
Elevation Oncology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elevation Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elevation Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Elevation Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Elevation Oncology Notable Stakeholders
An Elevation Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Elevation Oncology often face trade-offs trying to please all of them. Elevation Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Elevation Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| PMP CPA | CFO Secretary | Profile | |
| Joseph Ferra | Chief Officer | Profile | |
| Valerie MD | Chief Officer | Profile | |
| RPh PharmD | President, Founder | Profile | |
| Ryan Bloomer | Head CMC | Profile | |
| Biren Shah | Senior Development | Profile | |
| Brian Sullivan | VP Devel | Profile | |
| Candice Masse | Senior Relations | Profile | |
| Robert Yang | Senior Counsel | Profile | |
| David Dornan | Chief Officer | Profile |
About Elevation Oncology Management Performance
The success or failure of an entity such as Elevation Oncology often depends on how effective the management is. Elevation Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Elevation management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Elevation management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.48) | (0.51) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.96) | (0.91) |
Please note, the imprecision that can be found in Elevation Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elevation Oncology. Check Elevation Oncology's Beneish M Score to see the likelihood of Elevation Oncology's management manipulating its earnings.
Elevation Oncology Workforce Analysis
Traditionally, organizations such as Elevation Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Elevation Oncology within its industry.Elevation Oncology Manpower Efficiency
Return on Elevation Oncology Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 4.6M | |
| Working Capital Per Employee | 2.9M | |
| Working Capital Per Executive | 8.4M |
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.